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used ‘cell shape’ to speculate on ‘cell phenotype’ in thin-
sectioned tissues. Unfortunately as well, all antibodies
used, save for anti-FSP1, have well-recognized, multi-
ple specificities—this is the issue we were decrying in
the first place [1]. Briefly, 5′-NT, alpha-smooth muscle
actin, CD45, MHC class II, and Thy1 are found in mul-
tiple cell types, including fibroblasts. CD3 and CD4 are
coexpressed on some T cells with Fcc RIII chains, which
apparently were not blocked during staining. Their pub-
lication does not cover the Mac-series of markers from
our work, nor are they mentioned in their letter, some of
which were originally characterized in fibroblasts (refer-
ence [26] in [1]).
Finally, the correspondents cite a review of S100A4
suggesting FSP1 is expressed in a variety of cells [4].
Space precludes a full response. We agree that FSP1 is
expressed in metastatic tumor cells; these cells reuse the
molecular program of fibroblasts (reference [5] in [1]).
The review also cites the expression of S100A4 in human
monocytes/macrophages and granulocytes (reference
[27] in [4]). The problem is some of these cells were from
a tumor, S100A4 staining of ‘purified’ macrophages or
monocytes was not confirmed with secondary markers, fi-
brocytes circulating in blood were ignored (reference [24]
in [1]), and blood cells were ‘purified’ using adherence to
collagen or gelatin, both of which bind macrophages and
fibroblasts. While our data in mice recognize that a few
hematopoietic precursors in bone marrow briefly express
FSP1 [1], this expression is lost as lineages mature. Other
references in the review citing expression of S100A4 in
skin cells are refuted within the review (reference [29] in
[4]).
In our publication we did not use anti-FSP1 antibody,
but GFP under the control of the FSP1 promoter [1]. This
transgene provides greater sensitivity than antibody de-
tection, and still did not cross-stain with F4/80. We stand
by our work and the work of others not cited who have
reproduced our EMT and fibroblast results with FSP1
as marker. We thank the correspondents for their com-
ments, but feel our original interpretation is the correct
one [1].
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Questions about graft
surveillance
To the Editor: The randomized clinical trial by Malik
et al reported that ultrasound screening for graft stenosis
and preemptive angioplasty resulted in longer arteriove-
nous (A-V) graft patency compared to clinical monitor-
ing alone [1]. Although this appears to be a well-designed
study, the manuscript provides very sketchy details about
the outcomes. We have the following questions for the au-
thors: (1) The paper reports the total frequency of inter-
ventions (angioplasty or thrombectomy) in each group. It
would be very helpful to separate the two. Specifically, did
the overall frequency of angioplasty differ between the
two groups? Did the overall frequency of graft thrombo-
sis differ between the two groups? (2) How many of the
failures in each group were due to irreversible throm-
bosis, and how many due to infection? (3) What pro-
portion of the angioplasties in the ultrasound group was
triggered by abnormal clinical examination, and what
proportion was due to an abnormal ultrasound study?
(4) Did thrombosis-free graft survival differ between the
two study groups?
Two previous randomized clinical trials evaluating ul-
trasound monitoring did not observe an improvement
in graft survival [2, 3]. How do the authors account for
the discrepancy between their study and the previous re-
ports?
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Reply from the Authors
As we noticed, percutaneous interventions were
far more frequent than surgical revisions (96% vs.
4%). Specifically, in subjects screened only traditionally
(Group 2), 91% of interventions were percutaneous, 9%
surgical. As shown, subjects screened also by ultrasound
(Group 1) underwent more interventions per graft (2.1 ±
1.8 vs. 1.3 ± 1.0). Of them, 97.5% were percutaneous,
the remaining surgical. Basically, the groups differed in
the number of percutaneous interventions, while the rate
of surgical procedures was similar. Surgical interventions
were usually indicated in case of graft thrombosis, which
occurred later in Group 1.
Access infection necessitated graft extraction in four
subjects of group 1 and in three subjects of group 2—the
difference was not significant.
In group 1, 55% of angiographies were indicated by
the result of ultrasound. We discussed low sensitivity of
clinical diagnosis of access stenosis in our previous study
[1].
The main differences between our study and both
cited studies are in race and group size. Mentioned stud-
ies included approximately 33 subjects, mostly African
American, while we had over 90 participants per group,
all of them Caucasian.
In Ram’s study, the median graft age at inclusion was
94 and 196 days, respectively, while Lumsden and we
started to follow them at the time of access creation.
Another difference between our and both cited studies
was in the criterion of hemodynamically significant ac-
cess stenosis. We considered the stenosis significant only
when >50% reduction of lumen in B-mode was com-
bined with >doubling of peak blood velocity compared
to unaffected segment. This combination was strictly fol-
lowed and in uncertain results, the ultrasound was re-
peated 1 month after. Using this approach, we probably
indicated angiography later. We could only hypothesize
that untreated 50% stenosis is more stable than >60%
stenosis after successful angioplasty, as is experienced in
arterial interventions.
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Hepatitis C infection
and proteinuria
To the Editor: Derived from the NHANES III
database, it has been shown that hepatitis C infection
is independently associated with microalbuminuria [1];
however, no renal histologic data are available. We re-
port the case of a 45-old-year Caucasian nondiabetic
man with chronic hepatitis C who presented an isolated
(without hematuria or renal insufficiency) and constant
(based on repeated measurements of urinary albumin)
albuminuria (0.5 g per day), before interferon pegylated
and ribavirine treatment was started. His blood pres-
sure was normal (130/80 mm Hg) without treatment.
Any metabolic syndrome criteria [2] were not found.
Cryoglobulins remained undetectable as hepatitis C viral
load (by quantitative polymerase chain reaction tech-
nique). Transjugular kidney biopsy revealed a normal re-
nal parenchyma with only a slight mesangial IgA deposit
that could be explained by his liver status [3]. Moreover,
carotid Doppler study ruled out stenosis or thrombosis as
previously described by Ishizaka et al [4], who suggested
a relationship between hepatitis C infection and carotid
atherosclerosis.
The statistically significant age (older) and race
(African American) factors found to be strongly asso-
ciated with microalbuminuria in nondiabetic hepatitis C
[1] are not applicable in our adult Caucasian patient, who,
in addition, had controlled blood pressure. Pathophysi-
ology of isolated albuminuria in hepatitis C–infected pa-
tients remains unclear.
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